Founded in 2010, Binhui Biopharmaceutical Co., Ltd. is a leading independent company of oncolytic virus immunotherapy in China, devoting to research and development in OV for more than ten years. The company created the oncolytic virus (OV) technology platform, its first product has obtained 3 IND approvals for OV mono and combo therapies, and is the only product conducted multiple Phase II clinical trials for mono and combo therapies with OV in various indications in China, which showed promising therapeutic effect. In August 2021, BS001(OH2) injection was approved by the U.S. FDA for clinical trial of various indications in the US.
Based on leading oHSV2 immunotherapy platform, the company owns various pipeline and actively develop viral vector vaccine, recombinant protein vaccine, and nucleic acid vaccine, and develop potential applications from OV based platform.
The company has production workshop in line with GMP standards and FDA and NMPA agreed production process. Mastering full value chain from research to production could fulfill the process the clinical research and industrialization.
The company has visionary founder and experienced international management team. It is favored by Fortune Capital, Lapam Capital, Lepu Medical, Share Capital, CICG, Vertex Ventures and SZVC and other reputable venture capital and industry funds, supporting the development of company.